Menu
Search
|

Menu

Close
X

FibroGen Inc FGEN.OQ (NASDAQ Stock Exchange Global Select Market)

54.63 USD
-1.09 (-1.96%)
As of 4:00 PM EDT
chart
Previous Close 55.72
Open 55.47
Volume 225,432
3m Avg Volume 163,179
Today’s High 55.90
Today’s Low 53.77
52 Week High 68.15
52 Week Low 40.75
Shares Outstanding (mil) 84.33
Market Capitalization (mil) 4,419.07
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
76
FY17
129
FY16
180
FY15
181
EPS (USD)
FY18
-0.779
FY17
-1.031
FY16
-1.016
FY15
-1.530
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
30.34
6.55
Price to Book (MRQ)
vs sector
8.90
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
23.10
14.15
LT Debt to Equity (MRQ)
vs sector
23.10
11.31
Return on Investment (TTM)
vs sector
-11.36
12.83
Return on Equity (TTM)
vs sector
-19.15
14.95

EXECUTIVE LEADERSHIP

Thomas Neff
Chairman of the Board, Chief Executive Officer, Since 1993
Salary: $840,000.00
Bonus: $693,000.00
Pat Cotroneo
Chief Financial Officer, Since 2008
Salary: $453,000.00
Bonus: $249,150.00
K. Peony Yu
Chief Medical Officer, Since 2016
Salary: $525,000.00
Bonus: $393,750.00
Thomas Kearns
Lead Independent Director, Since 2017
Salary: --
Bonus: --
Jeffrey Edwards
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

409 Illinois St
SAN FRANCISCO   CA   94158-2509

Phone: +1415.9781200

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

SPONSORED STORIES